Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

New topical drug shows promise in preventing cutaneous squamous cell carcinoma

Cutaneous squamous cell carcinoma is the second most common type of skin cancer in the United States, impacting approximately 700,000 people each year.

11 Oct 2023

Study highlights YB-1 targeting as novel treatment approach for pleural mesothelioma

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options.

11 Oct 2023

Liquid biopsies could be used as an early marker of immunotherapy response, study finds

Liquid biopsies are blood tests that can serially measure circulating tumor DNA (cell-free DNA that is shed into the bloodstream by dying cancer cells).

9 Oct 2023

Drug combo safely decreases pancreatic cancer growth in mice

A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.

9 Oct 2023

AI model accurately forecasts patient outcomes for common lung cancer after surgery

Researchers develop an AI model to accurately predict prognosis for patients with non-small cell lung cancer after surgery. The model, which utilized a range of preoperative and postoperative blood test results, achieved high prediction accuracy, offering a promising approach for personalized treatment plans.

25 Sep 2023

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

21 Sep 2023

Researchers develop new approach to fighting chemo-resistant small cell lung cancer

Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate.

21 Sep 2023

Combination immunotherapy outperforms durvalumab monotherapy in neoadjuvant NSCLC

Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center.

14 Sep 2023

New trial shows promise of combination neoadjuvant immunotherapy for lung cancer

Patients with stage 1–3 non-small cell lung cancer (NSCLC) given a combination immunotherapy prior to surgery (neoadjuvant) had a better major pathological response (10% or less residual cancer) when the cancer was removed than those who took a single immunotherapy agent alone, according to results of a novel multicenter phase 2 NeoCOAST platform trial that included two investigators from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy.

14 Sep 2023

Researchers receive £2.66M to test new immunotherapeutic strategy for non-small cell lung cancer

University of Liverpool researchers have secured £2.66m Medical Research Council funding to clinically test a novel immunotherapeutic strategy for non-small cell lung cancer – one of the most deadly cancers.

13 Sep 2023

Study reveals key reproductive factors that may increase lung cancer risk in women

A study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer revealed that key reproductive factors such as early menopause, shortened reproductive span, and early age at first birth are associated with elevated risks of lung cancer in women.

12 Sep 2023

CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment.

11 Sep 2023

Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancer

The immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.

11 Sep 2023

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS® (sotorasib) for adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on Oct. 5, 2023.

From AMGEN 1 Sep 2023

The Clinical Importance of Circulating Tumor DNA

Cancer remains a leading killer among medical causes of death worldwide.

31 Aug 2023

New discoveries about a type of immune cells could pave the way for improved immunotherapies

Fresh discoveries about a type of immune cells could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.

30 Aug 2023

Non-traditional gene fusions in luminal breast cancer: A new target for therapy

A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?"

21 Aug 2023

Epigenetic manipulation may improve breast cancer treatment responses

Researchers explore the possibility of increasing TROP2 ADC activity by enhancing the expression of TROP2 on cancer cells.

15 Aug 2023

Pembrolizumab combination therapies effective for advanced NSCLC, study shows

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.

12 Jul 2023

Immunotherapy significantly improves overall survival for advanced NSCLC patients

A global study, led by UCL and UCLH and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with platinum-containing chemotherapy, when compared to single-agent chemotherapy.

6 Jul 2023